Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability, 45867-45872 [E9-21302]
Download as PDF
srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 74, No. 171 / Friday, September 4, 2009 / Notices
polypeptide capsule of poly-g-Dglutamic acid (gDPGA). gDPGA is poorly
immunogenic and has antiphagocytic
properties. The bacterial capsule is
essential for virulence. Antibodies to the
capsule have been shown to enhance
phagocytosis and killing of
encapsulated bacilli. These antibodies
in combination with antibodies that
neutralize the toxins of B. anthracis
could provide enhanced protection by
their dual antibacterial and antitoxic
activities. Such antibodies would be
especially useful for antibiotic-resistant
strains.
In order to obtain therapeutically
useful anti-g DPGA monoclonal
antibodies (MAbs), the inventors
immunized chimpanzees with
conjugates of 15-mer glutamic acid
polymers to immunogenic protein
carriers (recombinant protective antigen
(PA) of B. anthracis). After several
immunizations, chimpanzees developed
strong immune responses to gDPGA. A
combinatorial Fab library of mRNA
derived from the chimpanzee’s bone
marrow was prepared and eight (8)
distinct Fabs reactive with native
gDPGA were recovered. Two (2) of the
Fabs were converted into full-length IgG
with human g1 heavy chain constant
regions. These two (2) MAbs showed
strong opsonophagocytic killing of
bacilli in an in vitro assay. These two (2)
MAbs were also tested for protection of
mice challenged with virulent anthrax
spores and results showed that both
MAbs provided full or nearly full
protection at a dose of 0.3 mg, the
lowest dose tested, which is much more
potent than previously reported murine
anti-PGA MAbs. Since chimpanzee
immunoglobulins are virtually identical
to human immunoglobulins, these
chimpanzee anticapsule MAbs may
have clinically useful applications.
This application claims the antibody
compositions described above. Also
claimed are methods of treating or
preventing B. anthracis infection in a
mammalian host and isolated
polynucleotides comprising a
nucleotide sequence encoding the
antibodies of the technology.
Applications: Development of anthrax
vaccines, therapeutics and diagnostics.
Advantages: Strongly neutralizing
antibodies, known regulatory pathway,
potential for use as both a prophylaxis
and therapy.
Development Status: Preclinical
studies have been performed utilizing
the monoclonal antibodies of this
technology.
Inventors: Zhaochun Chen (NIAID),
Robert H. Purcell (NIAID), Joanna
Kubler-Kielb (NICHD), Lily Zhongdong
VerDate Nov<24>2008
17:16 Sep 03, 2009
Jkt 217001
Dai (NICHD), Rachel Schneerson
(NICHD).
Patent Status: U.S. Provisional
Application No. 61/116,222 filed 19
Nov 2008 (HHS Reference No. E–125–
2008/0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301–435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize MAbs neutralizing
anthrax toxins and capsule for
comprehensive protection against
anthrax. Please contact Bill Ronnenberg,
NIAID Office of Technology
Development, at 301–451–3522 for more
information.
Dated: August 28, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E9–21482 Filed 9–3–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Health
Promotion and Disease Prevention
Research Centers, Special Interest
Project Competitive Supplements
(SIPS) (U48 Panels A–M), RFA–DP09–
101SUPP09, Initial Review
Cancellation: The notice was
originally published in the Federal
Register on July 14, 2009 (Volume 74,
Number 133) [page 34026]. The
following panels are cancelled: D, F, K,
L and M.
Contact Person for More Information:
Brenda Colley-Gilbert, PhD, Director,
Extramural Research Program Office,
CCCH, 4770 Buford Highway, MS K–92,
Atlanta, GA 30341, Telephone (770)
488–6295.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
45867
Dated: August 26, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–21379 Filed 9–3–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0233]
Report on the Performance of Drug
and Biologics Firms in Conducting
Postmarketing Requirements and
Commitments; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
SUMMARY: Under the Food and Drug
Administration Modernization Act of
1997 (Modernization Act), the Food and
Drug Administration (FDA) is required
to report annually in the Federal
Register on the status of postmarketing
requirements and commitments
required of, or agreed upon, by holders
of approved drug and biological
products. This is the agency’s report on
the status of the studies and clinical
trials that applicants have agreed to or
are required to conduct.
FOR FURTHER INFORMATION CONTACT:
Cathryn C. Lee, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 6464,
Silver Spring, MD 20993–0002,
301–796–0700; or
Robert Yetter, Center for Biologics
Evaluation and Research (HFM–25),
Food and Drug Administration,
1400 Rockville Pike, Rockville, MD
20852, 301–827–0373.
SUPPLEMENTARY INFORMATION:
I. Background
A. The Modernization Act
Section 130(a) of the Modernization
Act (Public Law 105–115) amended the
Federal Food, Drug, and Cosmetic Act
(the act) by adding a new provision
requiring reports of certain
postmarketing studies, including
clinical trials, for human drug and
biological products (section 506B of the
act (21 U.S.C. 356(b)). Section 506B of
the act provides FDA with additional
authority to monitor the progress of a
postmarketing study or clinical trial that
an applicant has been required to or has
agreed to conduct by requiring the
applicant to submit a report annually
E:\FR\FM\04SEN1.SGM
04SEN1
45868
Federal Register / Vol. 74, No. 171 / Friday, September 4, 2009 / Notices
providing information on the status of
the postmarketing study/clinical trial.
This report must also include reasons, if
any, for failure to complete the study/
clinical trial. These studies and clinical
trials are intended to further define the
safety, efficacy, or optimal use of a
product and therefore play a vital role
in fully characterizing the product.
Under the Modernization Act,
commitments to conduct postmarketing
studies or clinical trials included both
studies/clinical trials that applicants
agreed to conduct as well as studies/
clinical trials that applicants were
required to conduct under FDA
regulations.1
srobinson on DSKHWCL6B1PROD with NOTICES
B. The Food and Drug Administration
Amendments Act of 2007
On September 27, 2007, the President
signed Public Law 110–85, the Food and
Drug Administration Amendments Act
of 2007 (FDAAA). Section 901, in Title
IX of FDAAA, created a new section
505(o) of the act authorizing FDA to
require certain studies and clinical trials
for human drug and biological products
approved under section 505 of the act or
section 351 of the Public Health Service
Act. Under FDAAA, FDA has been
given additional authority to require
applicants to conduct and report on
postmarketing studies and clinical trials
to assess a known serious risk, assess
signals of serious risk, or identify an
unexpected serious risk related to the
use of a product. This new authority
became effective on March 25, 2008.
FDA may now take enforcement action
against applicants who fail to conduct
studies and clinical trials required
under FDAAA, as well as studies and
clinical trials required under FDA
regulations (see sections 505(o)(1),
502(z), and 303(f) of the act; 21 U.S.C.
355(o)(1), 352(z), and 333(f)).
Although regulations implementing
the Modernization Act postmarketing
authorities use the term ‘‘postmarketing
commitment’’ to refer to both required
studies and studies applicants agree to
conduct, in light of the new authorities
enacted in FDAAA, FDA has decided it
is important to distinguish between
enforceable postmarketing requirements
and unenforceable postmarketing
commitments. Therefore, in this notice
1 FDA could require postmarketing studies and
clinical trials under the following circumstances:
To verify and describe clinical benefit for a human
drug approved in accordance with the accelerated
approval provisions (21 U.S.C. 356(b)(2)(A); 21 CFR
314.510 and 601.41); for a drug approved on the
basis of animal efficacy data because human
efficacy trials are not ethical or feasible (21 CFR
314.610(b)(1) and 601.91(b)(1)); and for marketed
drugs that are not adequately labeled for children
(Pediatric Research Equity Act (21 U.S.C. 355B;
Public Law 108–155)).
VerDate Nov<24>2008
17:16 Sep 03, 2009
Jkt 217001
and report, FDA refers to studies/
clinical trials that an applicant is
required to conduct as ‘‘postmarketing
requirements’’ (PMRs) and studies/
clinical trials that an applicant agrees to
but is not required to conduct as
‘‘postmarketing commitments’’ (PMCs).
Both are addressed in this notice and
report.
C. FDA’s Implementing Regulations
On October 30, 2000 (65 FR 64607),
FDA published a final rule
implementing section 130 of the
Modernization Act. This rule modified
the annual report requirements for new
drug applications (NDAs) and
abbreviated new drug applications
(ANDAs) by revising § 314.81(b)(2)(vii)
(21 CFR 314.81(b)(2)(vii)). The rule also
created a new annual reporting
requirement for biologics license
applications (BLAs) by establishing
§ 601.70 (21 CFR 601.70). The rule
described the content and format of the
annual progress report, and clarified the
scope of the reporting requirement and
the timing for submission of the annual
progress reports. The rule became
effective on April 30, 2001. The
regulations apply only to human drug
and biological products that are
approved under NDAs, ANDAs, and
BLAs. They do not apply to animal
drugs or to biological products regulated
under the medical device authorities.
The reporting requirements under
§§ 314.81(b)(2)(vii) and 601.70 apply to
PMRs and PMCs made on or before the
enactment of the Modernization Act
(November 21, 1997), as well as those
made after that date. Therefore, studies
and clinical trials required under
FDAAA are covered by the reporting
requirements in these regulations.
Sections 314.81(b)(2)(vii) and 601.70
require applicants of approved drug and
biological products to submit annually a
report on the status of each clinical
safety, clinical efficacy, clinical
pharmacology, and nonclinical
toxicology study/clinical trial that is
required by FDA or that they have
committed to conduct either at the time
of approval or after approval of their
NDA, ANDA, or BLA. The status of
PMCs concerning chemistry,
manufacturing, and production controls
and the status of other studies/clinical
trials conducted on an applicant’s own
initiative are not required to be reported
under §§ 314.81(b)(2)(vii) and 601.70
and are not addressed in this report. It
should be noted, however, that
applicants are required to report to FDA
on these commitments made for NDAs
and ANDAs under § 314.81(b)(2)(viii).
Furthermore, section 505(o)(1)(E) of the
act as amended by FDAAA requires that
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
applicants report periodically on the
status of each required study/clinical
trial and each study/clinical trial
‘‘otherwise undertaken * * * to
investigate a safety issue * * * .’’
According to the regulations, once a
PMR has been required or a PMC has
been agreed upon, an applicant must
report on the progress of the PMR/PMC
on the anniversary of the product’s
approval until the PMR/PMC is
completed or terminated and FDA
determines that the PMR/PMC has been
fulfilled or that the PMR/PMC is either
no longer feasible or would no longer
provide useful information. The annual
progress report must include a
description of the PMR/PMC, a schedule
for completing the PMR/PMC, and a
characterization of the current status of
the PMR/PMC. The report must also
provide an explanation of the PMR/PMC
status by describing briefly the progress
of the PMR/PMC. A PMR/PMC schedule
is expected to include the actual or
projected dates for the following: (1)
Submission of the final protocol to FDA,
(2) completion of subject accrual or
initiation of an animal study, (3)
completion of the study/clinical trial,
and (4) submission of the final report to
FDA. The status of the PMR/PMC must
be described in the annual report
according to the following definitions:
• Pending: The study/clinical trial
has not been initiated (i.e., no subjects
have been enrolled or animals dosed),
but does not meet the criteria for
delayed (i.e., the original projected date
for initiation of subject accrual or
initiation of animal dosing has not
passed);
• Ongoing: The study/clinical trial is
proceeding according to or ahead of the
original schedule;
• Delayed: The study/clinical trial is
behind the original schedule;
• Terminated: The study/clinical trial
was ended before completion, but a
final report has not been submitted to
FDA; or
• Submitted: The study/clinical trial
has been completed or terminated, and
a final report has been submitted to
FDA.
Databases containing information on
PMRs/PMCs are maintained at the
Center for Drug Evaluation and Research
(CDER) and the Center for Biologics
Evaluation and Research (CBER).
II. Summary of Information From
Postmarketing Status Reports
This report, published to fulfill the
annual reporting requirement under the
Modernization Act, summarizes the
status of PMRs and PMCs as of
September 30, 2008. If a requirement or
commitment did not have a schedule, or
E:\FR\FM\04SEN1.SGM
04SEN1
srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 74, No. 171 / Friday, September 4, 2009 / Notices
a postmarketing progress report was not
received in the previous 12 months, the
PMR/PMC is categorized according to
the most recent information available to
the agency.
Information in this report covers any
PMR/PMC that was made, in writing, at
the time of approval or after approval of
an application or a supplement to an
application, including PMRs required
under FDAAA (section 505(o)(3) of the
act), PMRs required under FDA
regulations (e.g., PMRs required to
demonstrate clinical benefit of a product
following accelerated approval (see
footnote 1 of this document)), and PMCs
agreed to by the applicant.
Information summarized in this report
includes the following: (1) The number
of applicants with open (uncompleted)
PMRs/PMCs, (2) the number of open
PMRs/PMCs, (3) the status of open
PMRs/PMCs as reported in
§ 314.81(b)(2)(vii) or § 601.70 annual
reports, (4) the status of concluded
PMRs/PMCs as determined by FDA, and
(5) the number of applications with
open PMRs/PMCs for which applicants
did not submit an annual report within
60 days of the anniversary date of U.S.
approval.
Additional information about PMRs/
PMCs submitted by applicants to CDER
and CBER is provided on FDA’s Web
site at https://www.fda.gov/Drugs/
GuidanceComplianceRegulatory
Information/Post-marketingPhaseIV
Commitments/default.htm. Neither the
Web site nor this notice include
information about PMCs concerning
chemistry, manufacturing, and controls.
It is FDA policy not to post information
on the Web site until it has been
reviewed for accuracy. Numbers
published in this notice cannot be
compared with the numbers resulting
from searches of the Web site because
this notice incorporates totals for all
PMRs/PMCs in FDA databases,
including PMRs/PMCs undergoing
review for accuracy. In addition, the
report in this notice will be updated
annually while the Web site is updated
quarterly (i.e., January, April, July, and
October).
Many applicants have more than one
approved product and for many
products there is more than one PMR or
PMC. Specifically, there were 158
unique applicants with 297 NDAs/
ANDAs that had open PMRs/PMCs.
VerDate Nov<24>2008
17:16 Sep 03, 2009
Jkt 217001
There were 54 unique applicants with
94 BLAs that had open PMRs/PMCs.
Annual status reports are required to
be submitted for each open PMR/PMC
within 60 days of the anniversary date
of U.S. approval of the original
application. In fiscal year (FY) 2008, 27
percent (59/215) of NDA/ANDA and 52
percent (43/83) of BLA annual status
reports were reported late or were
overdue at the close of the FY,
September 30, 2008. Of the annual
status reports due but not submitted
within 60 days of the anniversary date
of U.S. approval of the original
application, 100 percent (59/59) of the
NDA/ANDA and 42 percent (18/43) of
the BLA reports were submitted before
September 30, 2008.
Most PMRs are progressing on
schedule (95 percent for NDAs/ANDAs;
89 percent for BLAs). Most PMCs are
also progressing on schedule (96 percent
for NDAs/ANDAs; 78 percent for BLAs).
Most of the PMCs that are currently
listed in the database were developed
before the postmarketing requirements
section of FDAAA took effect.2
III. What’s New About This Report
This report now provides six separate
tables instead of one summary table.
The tables distinguish between PMRs
and PMCs and between on-schedule and
off-schedule PMRs and PMCs according
to the original schedule milestones. Onschedule PMRs/PMCs are categorized as
pending, ongoing, or submitted. Offschedule PMRs/PMCs that have missed
one of the original milestone dates are
categorized as delayed or terminated.
The tables include data as of September
30, 2008.
Table 1 of this document provides an
overall summary of the data on all PMRs
and PMCs. Tables 2 and 3 of this
document provide detail on PMRs.
Table 2 of this document provides
additional detail on the status of onschedule PMRs.
Table 1 of this document shows that
most PMRs (95 percent for NDAs/
ANDAs and 89 percent for BLAs) and
most PMCs (96 percent for NDAs/
ANDAs and 78 percent for BLAs) are on
2 Although there are PMCs that might meet
FDAAA standards for required safety studies/
clinical trials under section 505(o)(3)(B) of the act
(21 U.S.C. 355(o)(3)(B)) if they were first
determined to be necessary today, they may be
converted to PMRs only if FDA becomes aware of
new safety information.
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
45869
schedule. Overall, of the PMRs that are
pending (i.e., have not been initiated),
73 percent were created within the past
3 years.
Table 2 of this document shows that
most pending PMRs for both drug and
biological products are in response to
the Pediatric Research and Equity Act
(PREA), under which FDA requires
sponsors to study new drugs, when
appropriate, for pediatric populations.
Under section 505B(a)(3) of the act, the
initiation of these studies generally is
deferred until required safety
information from other studies has first
been submitted and reviewed. PMRs for
products approved under the animal
efficacy rule (21 CFR 314.600 for drugs;
21 CFR 601.90 for biological products)
can be conducted only when the
product is used for its indication as a
counterterrorism measure. In the
absence of a public health emergency,
these studies/clinical trials will remain
pending indefinitely. The next largest
category of pending PMRs comprises
those studies/clinical trials required by
FDA under FDAAA, which became
effective on March 25, 2008.
Section 921 of FDAAA requires FDA
to review the backlog of postmarketing
safety commitments and report to
Congress. CDER contracted with an
external group to review the backlog of
its PMRs/PMCs as well as PMR/PMC
annual status reports.3 The contractors’s
report was recently completed and can
be found on the FDA Web site at https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/PostmarketingPhaseIVCommitments/
ucm064436.htm. As Exhibit 9 of the
report shows, the external review has
resulted in a decreased number of NDA
PMRs/PMCs categorized as pending
because their statuses have been
updated to other categories (e.g.,
submitted). Some of this decrease is
reflected in the NDA statistics reported
in this notice, which shows the status of
the PMRs/PMCs as of September 30,
2008, and additional status changes will
be reflected in the statistics reported in
the next annual notice showing the
status of the PMRs/PMCs as of
September 30, 2009.
3 The external backlog review covered PMRs/
PMCs for NDAs and CDER-regulated BLAs. CBER
conducted a separate backlog review of the CBERregulated BLAs.
E:\FR\FM\04SEN1.SGM
04SEN1
45870
Federal Register / Vol. 74, No. 171 / Friday, September 4, 2009 / Notices
Table 3 of this document provides
additional detail on the status of offschedule PMRs. The majority of offschedule PMRs (which account for only
5 percent of the total for NDAs/ANDAs
and 11 percent for BLAs) are delayed
according to the original schedule
milestones (93 percent (13/14) for
NDAs/ANDAs; 71 percent (5/7) for
BLAs). However, after discussion
between FDA and applicants, the
original schedules may have been
adjusted for unanticipated delays in the
progress of the study/clinical trial (e.g.,
difficulties with subject enrollment in a
trial for a marketed drug or need for
additional time to analyze results). In
this report, study status reflects the
status in relation to the original study
schedule regardless of whether
adjustments to the schedule have been
made.
Tables 4 and 5 of this document
provide additional detail on the status
of PMCs. Table 4 provides additional
detail on the status of on-schedule
PMCs. Pending PMCs comprise 56
percent (544/965) of the on-schedule
NDA and ANDA PMCs and 40 percent
(112/279) of the on-schedule BLA
PMCs.
Table 5 of this document provides
additional details on the status of offschedule PMCs. The majority of offschedule PMCs (which account for only
4 percent for NDAs/ANDAs and 22
percent for BLAs) are delayed according
to the original schedule milestones (91
percent (39/43) for NDAs/ANDAs; 97
percent (76/78) for BLAs). However,
after discussion between FDA and
applicants, the original schedules may
have been adjusted for unanticipated
delays in the progress of the study/
clinical trial (e.g., difficulties with
subject enrollment in a trial for a
marketed drug or need for additional
time to analyze results).
Table 6 of this document provides
details about PMRs and PMCs that were
concluded in the previous year. Most
concluded PMRs and PMCs were
fulfilled (80 percent of NDA/ANDA
PMRs and 70 percent of BLA PMRs; 86
percent of NDA/ANDA PMCs and 97
percent of BLA PMCs).
TABLE 1.—SUMMARY OF POSTMARKETING REQUIREMENTS AND COMMITMENTS (NUMBERS AS OF SEPTEMBER 30, 2008)
NDA/ANDA (% of Total PMR
or % of Total PMC)
Number of open PMRs
BLA (% of Total PMR or % of
Total PMC)1
306
65
On-schedule open PMRs (see table 2 of this document)
292 (95%)
58 (89%)
Off-schedule open PMRs (see table 3 of this document)
14 (5%)
7 (11%)
1,008
357
On-schedule open PMCs (see table 4 of this document)
965 (96%)
279 (78%)
Off-schedule open PMCs (see table 5 of this document)
43 (4%)
78 (22%)
Number of open PMCs
1 On October 1, 2003, FDA completed a consolidation of certain therapeutic products formerly regulated by CBER into CDER. Consequently,
CDER now reviews many BLAs. Fiscal year statistics for postmarketing requirements and commitments for BLAs reviewed by CDER are included in BLA totals in this table.
TABLE 2.—SUMMARY OF ON-SCHEDULE POSTMARKETING REQUIREMENTS (NUMBERS AS OF SEPTEMBER 30, 2008)
On-Schedule Open PMRs
NDA/ANDA (% of Total PMR)
BLA (% of Total PMR)1
Pending by type
Accelerated approval
15
3
194
24
2
0
30
12
241 (79%)
39 (60%)
Accelerated approval
17
3
PREA2
13
6
Animal efficacy3
0
0
FDAAA safety (since March 25, 2008)
0
4
30 (10%)
13 (20%)
12
2
9
4
PREA2
Animal efficacy3
FDAAA safety (since March 25, 2008)
Total
srobinson on DSKHWCL6B1PROD with NOTICES
Ongoing
Total
Submitted
Accelerated approval
PREA2
VerDate Nov<24>2008
17:16 Sep 03, 2009
Jkt 217001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
E:\FR\FM\04SEN1.SGM
04SEN1
Federal Register / Vol. 74, No. 171 / Friday, September 4, 2009 / Notices
45871
TABLE 2.—SUMMARY OF ON-SCHEDULE POSTMARKETING REQUIREMENTS (NUMBERS AS OF SEPTEMBER 30, 2008)—
Continued
On-Schedule Open PMRs
NDA/ANDA (% of Total PMR)
BLA (% of Total PMR)1
Animal efficacy3
0
0
FDAAA safety (since March 25, 2008)
0
0
21 (12%)
6 (9%)
292 (95%)
58 (89%)
Total
Combined Total
1 See
note 1 for table 1 of this document.
PREA studies have a pending status. PREA studies are usually deferred because the product is ready for approval in adults. Initiation
of these studies also may be deferred until additional safety information from other studies has first been submitted and reviewed.
3 PMRs for products approved under the animal efficacy rule (21 CFR 314.600 for drugs; 21 CFR 601.90 for biological products) can be conducted only when the product is used for its indication as a counterterrorism measure. In the absence of a public health emergency, these studies/clinical trials will remain pending indefinitely.
2 Many
TABLE 3.—SUMMARY OF OFF-SCHEDULE POSTMARKETING REQUIREMENTS (NUMBERS AS OF SEPTEMBER 30, 2008)
Off-Schedule Open PMRs
NDA/ANDA (% of Total PMR)
BLA (% of Total PMR)1
Delayed
Accelerated approval
4
2
PREA
9
3
Animal efficacy
0
0
FDAAA safety (since March 25, 2008)
0
0
13 (4%)
5 (8%)
Terminated
1 (0.3%)
2 (3%)
Combined total
14 (5%)
7 (11%)
Total
1 See
note 1 for table 1 of this document.
TABLE 4.—SUMMARY OF ON-SCHEDULE POSTMARKETING COMMITMENTS (NUMBERS AS OF SEPTEMBER 30, 2008)
On-Schedule Open PMCs
NDA/ANDA (% of Total PMC)
BLA (% of Total PMC)1
Pending
544 (54%)
112 (31%)
Ongoing
166 (17%)
93 (26%)
Submitted
255 (25%)
74 (21%)
Combined total
965 (96%)
279 (78%)
1 See
note 1 for table 1 of this document.
TABLE 5.—SUMMARY OF OFF-SCHEDULE POSTMARKETING COMMITMENTS (NUMBERS AS OF SEPTEMBER 30, 2008)
Off-Schedule Open PMCs
NDA/ANDA (% of Total PMC)
BLA (% of Total PMC)1
Delayed
39 (4%)
76 (21%)
Terminated
4 (0.4%)
2 (1%)
Combined total
43 (4%)
78 (22%)
srobinson on DSKHWCL6B1PROD with NOTICES
1 See
note 1 for table 1 of this document.
TABLE 6.—SUMMARY OF CONCLUDED POSTMARKETING REQUIREMENTS AND COMMITMENTS (OCTOBER 1, 2007 TO
OCTOBER 1, 2008)
NDA/ANDA (% of Total)
BLA (% of Total)1
Concluded PMRs
Requirement met (fulfilled)
VerDate Nov<24>2008
17:16 Sep 03, 2009
12 (80%)
Jkt 217001
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
E:\FR\FM\04SEN1.SGM
04SEN1
7 (70%)
45872
Federal Register / Vol. 74, No. 171 / Friday, September 4, 2009 / Notices
TABLE 6.—SUMMARY OF CONCLUDED POSTMARKETING REQUIREMENTS AND COMMITMENTS (OCTOBER 1, 2007 TO
OCTOBER 1, 2008)—Continued
BLA (% of Total)1
NDA/ANDA (% of Total)
Requirement not met (released and new revised requirement issued)
1 (7%)
2 (13%)
3 (30%)
15
10
94 (86%)
30 (97%)
3 (3%)
0
12 (11%)
1 (3%)
109
Requirement no longer feasible or product withdrawn (released)
0
31
Total
Concluded PMCs
Commitment met (fulfilled)
Commitment not met (released and new revised requirement/commitment
issued)
Commitment no longer feasible or product withdrawn (released)
Total
1 See
note 1 for table 1 of this document.
Dated: August 31, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–21302 Filed 9–3–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Agency Information Collection
Activities: Application for Allowance in
Duties
srobinson on DSKHWCL6B1PROD with NOTICES
AGENCY: U.S. Customs and Border
Protection (CBP), Department of
Homeland Security.
ACTION: 60-Day notice and request for
comments; extension of an existing
collection of information: 1651–0007.
SUMMARY: As part of its continuing effort
to reduce paperwork and respondent
burden, CBP invites the general public
and other Federal agencies to comment
on an information collection
requirement concerning the Application
for Allowance in Duties. This request
for comment is being made pursuant to
the Paperwork Reduction Act of 1995
(Pub. L. 104–13; 44 U.S.C. 3505(c)(2)).
DATES: Written comments should be
received on or before November 3, 2009,
to be assured of consideration.
ADDRESSES: Direct all written comments
to U.S. Customs and Border Protection,
Attn: Tracey Denning, Office of
Regulations and Rulings, 799 9th Street,
NW., 7th Floor, Washington, DC 20229–
1177.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information
should be directed to Tracey Denning,
U.S. Customs and Border Protection,
VerDate Nov<24>2008
18:52 Sep 03, 2009
Jkt 217001
Office of Regulations and Rulings, 799
9th Street, NW., 7th Floor, Washington,
DC 20229–1177, at 202–325–0265.
SUPPLEMENTARY INFORMATION: CBP
invites the general public and other
Federal agencies to comment on
proposed and/or continuing information
collections pursuant to the Paperwork
Reduction Act of 1995 (Pub. L. 104–13;
44 U.S.C. 3505(c)(2)). The comments
should address: (a) Whether the
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimates of the burden of the
collection of information; (c) ways to
enhance the quality, utility, and clarity
of the information to be collected; (d)
ways to minimize the burden including
the use of automated collection
techniques or the use of other forms of
information technology; and (e) the
annual cost burden to respondents or
recordkeepers from the collection of
information (total capital/startup costs
and operations and maintenance costs).
The comments that are submitted will
be summarized and included in the CBP
request for Office of Management and
Budget (OMB) approval. All comments
will become a matter of public record.
In this document CBP is soliciting
comments concerning the following
information collection:
Title: Application for Allowance in
Duties.
OMB Number: 1651–0007.
Form Number: CBP Form 4315.
Abstract: Form 4315 is required by
CBP in instances of claims of damaged
or defective imported merchandise on
which an allowance in duty is made in
the liquidation of an entry. The
information is used to substantiate an
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
importer’s claim for such duty
allowances.
Current Actions: There are no changes
to the information collection. This
submission is being made to extend the
expiration date.
Type of Review: Extension (without
change).
Affected Public: Businesses.
Estimated Number of Respondents:
12,000.
Estimated Number of Annual
Responses per Respondent: 1.
Estimated Time per Respondent: 8
minutes.
Estimated Total Annual Burden
Hours: 1,600.
Dated: September 1, 2009.
Tracey Denning,
Agency Clearance Officer, Customs and
Border Protection.
[FR Doc. E9–21366 Filed 9–3–09; 8:45 am]
BILLING CODE 9111–14–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5285–N–28]
Notice of Proposed Information
Collection: Comment Request;
Request for Approval of Advance of
Escrow Funds
AGENCY: Office of the Assistant
Secretary for Housing, HUD.
ACTION: Notice.
SUMMARY: The proposed information
collection requirement described below
will be submitted to the Office of
Management and Budget (OMB) for
review, as required by the Paperwork
Reduction Act. The Department is
soliciting public comments on the
subject proposal.
E:\FR\FM\04SEN1.SGM
04SEN1
Agencies
[Federal Register Volume 74, Number 171 (Friday, September 4, 2009)]
[Notices]
[Pages 45867-45872]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21302]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0233]
Report on the Performance of Drug and Biologics Firms in
Conducting Postmarketing Requirements and Commitments; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: Under the Food and Drug Administration Modernization Act of
1997 (Modernization Act), the Food and Drug Administration (FDA) is
required to report annually in the Federal Register on the status of
postmarketing requirements and commitments required of, or agreed upon,
by holders of approved drug and biological products. This is the
agency's report on the status of the studies and clinical trials that
applicants have agreed to or are required to conduct.
FOR FURTHER INFORMATION CONTACT:
Cathryn C. Lee, Center for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 6464,
Silver Spring, MD 20993-0002, 301-796-0700; or
Robert Yetter, Center for Biologics Evaluation and Research (HFM-
25), Food and Drug Administration, 1400 Rockville Pike, Rockville, MD
20852, 301-827-0373.
SUPPLEMENTARY INFORMATION:
I. Background
A. The Modernization Act
Section 130(a) of the Modernization Act (Public Law 105-115)
amended the Federal Food, Drug, and Cosmetic Act (the act) by adding a
new provision requiring reports of certain postmarketing studies,
including clinical trials, for human drug and biological products
(section 506B of the act (21 U.S.C. 356(b)). Section 506B of the act
provides FDA with additional authority to monitor the progress of a
postmarketing study or clinical trial that an applicant has been
required to or has agreed to conduct by requiring the applicant to
submit a report annually
[[Page 45868]]
providing information on the status of the postmarketing study/clinical
trial. This report must also include reasons, if any, for failure to
complete the study/clinical trial. These studies and clinical trials
are intended to further define the safety, efficacy, or optimal use of
a product and therefore play a vital role in fully characterizing the
product.
Under the Modernization Act, commitments to conduct postmarketing
studies or clinical trials included both studies/clinical trials that
applicants agreed to conduct as well as studies/clinical trials that
applicants were required to conduct under FDA regulations.\1\
---------------------------------------------------------------------------
\1\ FDA could require postmarketing studies and clinical trials
under the following circumstances: To verify and describe clinical
benefit for a human drug approved in accordance with the accelerated
approval provisions (21 U.S.C. 356(b)(2)(A); 21 CFR 314.510 and
601.41); for a drug approved on the basis of animal efficacy data
because human efficacy trials are not ethical or feasible (21 CFR
314.610(b)(1) and 601.91(b)(1)); and for marketed drugs that are not
adequately labeled for children (Pediatric Research Equity Act (21
U.S.C. 355B; Public Law 108-155)).
---------------------------------------------------------------------------
B. The Food and Drug Administration Amendments Act of 2007
On September 27, 2007, the President signed Public Law 110-85, the
Food and Drug Administration Amendments Act of 2007 (FDAAA). Section
901, in Title IX of FDAAA, created a new section 505(o) of the act
authorizing FDA to require certain studies and clinical trials for
human drug and biological products approved under section 505 of the
act or section 351 of the Public Health Service Act. Under FDAAA, FDA
has been given additional authority to require applicants to conduct
and report on postmarketing studies and clinical trials to assess a
known serious risk, assess signals of serious risk, or identify an
unexpected serious risk related to the use of a product. This new
authority became effective on March 25, 2008. FDA may now take
enforcement action against applicants who fail to conduct studies and
clinical trials required under FDAAA, as well as studies and clinical
trials required under FDA regulations (see sections 505(o)(1), 502(z),
and 303(f) of the act; 21 U.S.C. 355(o)(1), 352(z), and 333(f)).
Although regulations implementing the Modernization Act
postmarketing authorities use the term ``postmarketing commitment'' to
refer to both required studies and studies applicants agree to conduct,
in light of the new authorities enacted in FDAAA, FDA has decided it is
important to distinguish between enforceable postmarketing requirements
and unenforceable postmarketing commitments. Therefore, in this notice
and report, FDA refers to studies/clinical trials that an applicant is
required to conduct as ``postmarketing requirements'' (PMRs) and
studies/clinical trials that an applicant agrees to but is not required
to conduct as ``postmarketing commitments'' (PMCs). Both are addressed
in this notice and report.
C. FDA's Implementing Regulations
On October 30, 2000 (65 FR 64607), FDA published a final rule
implementing section 130 of the Modernization Act. This rule modified
the annual report requirements for new drug applications (NDAs) and
abbreviated new drug applications (ANDAs) by revising Sec.
314.81(b)(2)(vii) (21 CFR 314.81(b)(2)(vii)). The rule also created a
new annual reporting requirement for biologics license applications
(BLAs) by establishing Sec. 601.70 (21 CFR 601.70). The rule described
the content and format of the annual progress report, and clarified the
scope of the reporting requirement and the timing for submission of the
annual progress reports. The rule became effective on April 30, 2001.
The regulations apply only to human drug and biological products that
are approved under NDAs, ANDAs, and BLAs. They do not apply to animal
drugs or to biological products regulated under the medical device
authorities.
The reporting requirements under Sec. Sec. 314.81(b)(2)(vii) and
601.70 apply to PMRs and PMCs made on or before the enactment of the
Modernization Act (November 21, 1997), as well as those made after that
date. Therefore, studies and clinical trials required under FDAAA are
covered by the reporting requirements in these regulations.
Sections 314.81(b)(2)(vii) and 601.70 require applicants of
approved drug and biological products to submit annually a report on
the status of each clinical safety, clinical efficacy, clinical
pharmacology, and nonclinical toxicology study/clinical trial that is
required by FDA or that they have committed to conduct either at the
time of approval or after approval of their NDA, ANDA, or BLA. The
status of PMCs concerning chemistry, manufacturing, and production
controls and the status of other studies/clinical trials conducted on
an applicant's own initiative are not required to be reported under
Sec. Sec. 314.81(b)(2)(vii) and 601.70 and are not addressed in this
report. It should be noted, however, that applicants are required to
report to FDA on these commitments made for NDAs and ANDAs under Sec.
314.81(b)(2)(viii). Furthermore, section 505(o)(1)(E) of the act as
amended by FDAAA requires that applicants report periodically on the
status of each required study/clinical trial and each study/clinical
trial ``otherwise undertaken * * * to investigate a safety issue * * *
.''
According to the regulations, once a PMR has been required or a PMC
has been agreed upon, an applicant must report on the progress of the
PMR/PMC on the anniversary of the product's approval until the PMR/PMC
is completed or terminated and FDA determines that the PMR/PMC has been
fulfilled or that the PMR/PMC is either no longer feasible or would no
longer provide useful information. The annual progress report must
include a description of the PMR/PMC, a schedule for completing the
PMR/PMC, and a characterization of the current status of the PMR/PMC.
The report must also provide an explanation of the PMR/PMC status by
describing briefly the progress of the PMR/PMC. A PMR/PMC schedule is
expected to include the actual or projected dates for the following:
(1) Submission of the final protocol to FDA, (2) completion of subject
accrual or initiation of an animal study, (3) completion of the study/
clinical trial, and (4) submission of the final report to FDA. The
status of the PMR/PMC must be described in the annual report according
to the following definitions:
Pending: The study/clinical trial has not been initiated
(i.e., no subjects have been enrolled or animals dosed), but does not
meet the criteria for delayed (i.e., the original projected date for
initiation of subject accrual or initiation of animal dosing has not
passed);
Ongoing: The study/clinical trial is proceeding according
to or ahead of the original schedule;
Delayed: The study/clinical trial is behind the original
schedule;
Terminated: The study/clinical trial was ended before
completion, but a final report has not been submitted to FDA; or
Submitted: The study/clinical trial has been completed or
terminated, and a final report has been submitted to FDA.
Databases containing information on PMRs/PMCs are maintained at the
Center for Drug Evaluation and Research (CDER) and the Center for
Biologics Evaluation and Research (CBER).
II. Summary of Information From Postmarketing Status Reports
This report, published to fulfill the annual reporting requirement
under the Modernization Act, summarizes the status of PMRs and PMCs as
of September 30, 2008. If a requirement or commitment did not have a
schedule, or
[[Page 45869]]
a postmarketing progress report was not received in the previous 12
months, the PMR/PMC is categorized according to the most recent
information available to the agency.
Information in this report covers any PMR/PMC that was made, in
writing, at the time of approval or after approval of an application or
a supplement to an application, including PMRs required under FDAAA
(section 505(o)(3) of the act), PMRs required under FDA regulations
(e.g., PMRs required to demonstrate clinical benefit of a product
following accelerated approval (see footnote 1 of this document)), and
PMCs agreed to by the applicant.
Information summarized in this report includes the following: (1)
The number of applicants with open (uncompleted) PMRs/PMCs, (2) the
number of open PMRs/PMCs, (3) the status of open PMRs/PMCs as reported
in Sec. 314.81(b)(2)(vii) or Sec. 601.70 annual reports, (4) the
status of concluded PMRs/PMCs as determined by FDA, and (5) the number
of applications with open PMRs/PMCs for which applicants did not submit
an annual report within 60 days of the anniversary date of U.S.
approval.
Additional information about PMRs/PMCs submitted by applicants to
CDER and CBER is provided on FDA's Web site at https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/default.htm. Neither the Web site nor this
notice include information about PMCs concerning chemistry,
manufacturing, and controls. It is FDA policy not to post information
on the Web site until it has been reviewed for accuracy. Numbers
published in this notice cannot be compared with the numbers resulting
from searches of the Web site because this notice incorporates totals
for all PMRs/PMCs in FDA databases, including PMRs/PMCs undergoing
review for accuracy. In addition, the report in this notice will be
updated annually while the Web site is updated quarterly (i.e.,
January, April, July, and October).
Many applicants have more than one approved product and for many
products there is more than one PMR or PMC. Specifically, there were
158 unique applicants with 297 NDAs/ANDAs that had open PMRs/PMCs.
There were 54 unique applicants with 94 BLAs that had open PMRs/PMCs.
Annual status reports are required to be submitted for each open
PMR/PMC within 60 days of the anniversary date of U.S. approval of the
original application. In fiscal year (FY) 2008, 27 percent (59/215) of
NDA/ANDA and 52 percent (43/83) of BLA annual status reports were
reported late or were overdue at the close of the FY, September 30,
2008. Of the annual status reports due but not submitted within 60 days
of the anniversary date of U.S. approval of the original application,
100 percent (59/59) of the NDA/ANDA and 42 percent (18/43) of the BLA
reports were submitted before September 30, 2008.
Most PMRs are progressing on schedule (95 percent for NDAs/ANDAs;
89 percent for BLAs). Most PMCs are also progressing on schedule (96
percent for NDAs/ANDAs; 78 percent for BLAs). Most of the PMCs that are
currently listed in the database were developed before the
postmarketing requirements section of FDAAA took effect.\2\
---------------------------------------------------------------------------
\2\ Although there are PMCs that might meet FDAAA standards for
required safety studies/clinical trials under section 505(o)(3)(B)
of the act (21 U.S.C. 355(o)(3)(B)) if they were first determined to
be necessary today, they may be converted to PMRs only if FDA
becomes aware of new safety information.
---------------------------------------------------------------------------
III. What's New About This Report
This report now provides six separate tables instead of one summary
table. The tables distinguish between PMRs and PMCs and between on-
schedule and off-schedule PMRs and PMCs according to the original
schedule milestones. On-schedule PMRs/PMCs are categorized as pending,
ongoing, or submitted. Off-schedule PMRs/PMCs that have missed one of
the original milestone dates are categorized as delayed or terminated.
The tables include data as of September 30, 2008.
Table 1 of this document provides an overall summary of the data on
all PMRs and PMCs. Tables 2 and 3 of this document provide detail on
PMRs. Table 2 of this document provides additional detail on the status
of on-schedule PMRs.
Table 1 of this document shows that most PMRs (95 percent for NDAs/
ANDAs and 89 percent for BLAs) and most PMCs (96 percent for NDAs/ANDAs
and 78 percent for BLAs) are on schedule. Overall, of the PMRs that are
pending (i.e., have not been initiated), 73 percent were created within
the past 3 years.
Table 2 of this document shows that most pending PMRs for both drug
and biological products are in response to the Pediatric Research and
Equity Act (PREA), under which FDA requires sponsors to study new
drugs, when appropriate, for pediatric populations. Under section
505B(a)(3) of the act, the initiation of these studies generally is
deferred until required safety information from other studies has first
been submitted and reviewed. PMRs for products approved under the
animal efficacy rule (21 CFR 314.600 for drugs; 21 CFR 601.90 for
biological products) can be conducted only when the product is used for
its indication as a counterterrorism measure. In the absence of a
public health emergency, these studies/clinical trials will remain
pending indefinitely. The next largest category of pending PMRs
comprises those studies/clinical trials required by FDA under FDAAA,
which became effective on March 25, 2008.
Section 921 of FDAAA requires FDA to review the backlog of
postmarketing safety commitments and report to Congress. CDER
contracted with an external group to review the backlog of its PMRs/
PMCs as well as PMR/PMC annual status reports.\3\ The contractors's
report was recently completed and can be found on the FDA Web site at
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/ucm064436.htm. As Exhibit 9 of the report
shows, the external review has resulted in a decreased number of NDA
PMRs/PMCs categorized as pending because their statuses have been
updated to other categories (e.g., submitted). Some of this decrease is
reflected in the NDA statistics reported in this notice, which shows
the status of the PMRs/PMCs as of September 30, 2008, and additional
status changes will be reflected in the statistics reported in the next
annual notice showing the status of the PMRs/PMCs as of September 30,
2009.
---------------------------------------------------------------------------
\3\ The external backlog review covered PMRs/PMCs for NDAs and
CDER-regulated BLAs. CBER conducted a separate backlog review of the
CBER-regulated BLAs.
---------------------------------------------------------------------------
[[Page 45870]]
Table 3 of this document provides additional detail on the status
of off-schedule PMRs. The majority of off-schedule PMRs (which account
for only 5 percent of the total for NDAs/ANDAs and 11 percent for BLAs)
are delayed according to the original schedule milestones (93 percent
(13/14) for NDAs/ANDAs; 71 percent (5/7) for BLAs). However, after
discussion between FDA and applicants, the original schedules may have
been adjusted for unanticipated delays in the progress of the study/
clinical trial (e.g., difficulties with subject enrollment in a trial
for a marketed drug or need for additional time to analyze results). In
this report, study status reflects the status in relation to the
original study schedule regardless of whether adjustments to the
schedule have been made.
Tables 4 and 5 of this document provide additional detail on the
status of PMCs. Table 4 provides additional detail on the status of on-
schedule PMCs. Pending PMCs comprise 56 percent (544/965) of the on-
schedule NDA and ANDA PMCs and 40 percent (112/279) of the on-schedule
BLA PMCs.
Table 5 of this document provides additional details on the status
of off-schedule PMCs. The majority of off-schedule PMCs (which account
for only 4 percent for NDAs/ANDAs and 22 percent for BLAs) are delayed
according to the original schedule milestones (91 percent (39/43) for
NDAs/ANDAs; 97 percent (76/78) for BLAs). However, after discussion
between FDA and applicants, the original schedules may have been
adjusted for unanticipated delays in the progress of the study/clinical
trial (e.g., difficulties with subject enrollment in a trial for a
marketed drug or need for additional time to analyze results).
Table 6 of this document provides details about PMRs and PMCs that
were concluded in the previous year. Most concluded PMRs and PMCs were
fulfilled (80 percent of NDA/ANDA PMRs and 70 percent of BLA PMRs; 86
percent of NDA/ANDA PMCs and 97 percent of BLA PMCs).
Table 1.--Summary of Postmarketing Requirements and Commitments (Numbers
as of September 30, 2008)
------------------------------------------------------------------------
NDA/ANDA (% of Total PMR or BLA (% of Total PMR or % of
% of Total PMC) Total PMC)\1\
------------------------------------------------------------------------
Number of 306 65
open PMRs
------------------------------------------------------------------------
On- 292 (95%) 58 (89%)
schedule
open PMRs
(see
table 2
of this
document)
------------------------------------------------------------------------
Off- 14 (5%) 7 (11%)
schedule
open PMRs
(see
table 3
of this
document)
------------------------------------------------------------------------
Number of 1,008 357
open PMCs
------------------------------------------------------------------------
On- 965 (96%) 279 (78%)
schedule
open PMCs
(see
table 4
of this
document)
------------------------------------------------------------------------
Off- 43 (4%) 78 (22%)
schedule
open PMCs
(see
table 5
of this
document)
------------------------------------------------------------------------
\1\ On October 1, 2003, FDA completed a consolidation of certain
therapeutic products formerly regulated by CBER into CDER.
Consequently, CDER now reviews many BLAs. Fiscal year statistics for
postmarketing requirements and commitments for BLAs reviewed by CDER
are included in BLA totals in this table.
Table 2.--Summary of On-Schedule Postmarketing Requirements (Numbers as
of September 30, 2008)
------------------------------------------------------------------------
On-Schedule
Open PMRs NDA/ANDA (% of Total PMR) BLA (% of Total PMR)\1\
------------------------------------------------------------------------
Pending by type
------------------------------------------------------------------------
Accelerate 15 3
d
approval
------------------------------------------------------------------------
PREA\2\ 194 24
------------------------------------------------------------------------
Animal 2 0
efficacy\
3\
------------------------------------------------------------------------
FDAAA 30 12
safety
(since
March 25,
2008)
------------------------------------------------------------------------
Total 241 (79%) 39 (60%)
------------------------------------------------------------------------
Ongoing
------------------------------------------------------------------------
Accelerate 17 3
d
approval
------------------------------------------------------------------------
PREA\2\ 13 6
------------------------------------------------------------------------
Animal 0 0
efficacy\
3\
------------------------------------------------------------------------
FDAAA 0 4
safety
(since
March 25,
2008)
------------------------------------------------------------------------
Total 30 (10%) 13 (20%)
------------------------------------------------------------------------
Submitted
------------------------------------------------------------------------
Accelerate 12 2
d
approval
------------------------------------------------------------------------
PREA\2\ 9 4
------------------------------------------------------------------------
[[Page 45871]]
Animal 0 0
efficacy\
3\
------------------------------------------------------------------------
FDAAA 0 0
safety
(since
March 25,
2008)
------------------------------------------------------------------------
Total 21 (12%) 6 (9%)
------------------------------------------------------------------------
Combined 292 (95%) 58 (89%)
Total
------------------------------------------------------------------------
\1\ See note 1 for table 1 of this document.
\2\ Many PREA studies have a pending status. PREA studies are usually
deferred because the product is ready for approval in adults.
Initiation of these studies also may be deferred until additional
safety information from other studies has first been submitted and
reviewed.
\3\ PMRs for products approved under the animal efficacy rule (21 CFR
314.600 for drugs; 21 CFR 601.90 for biological products) can be
conducted only when the product is used for its indication as a
counterterrorism measure. In the absence of a public health emergency,
these studies/clinical trials will remain pending indefinitely.
Table 3.--Summary of Off-Schedule Postmarketing Requirements (Numbers as
of September 30, 2008)
------------------------------------------------------------------------
Off-Schedule
Open PMRs NDA/ANDA (% of Total PMR) BLA (% of Total PMR)\1\
------------------------------------------------------------------------
Delayed
------------------------------------------------------------------------
Accelerate 4 2
d
approval
------------------------------------------------------------------------
PREA 9 3
------------------------------------------------------------------------
Animal 0 0
efficacy
------------------------------------------------------------------------
FDAAA 0 0
safety
(since
March 25,
2008)
------------------------------------------------------------------------
Total 13 (4%) 5 (8%)
------------------------------------------------------------------------
Terminated 1 (0.3%) 2 (3%)
------------------------------------------------------------------------
Combined 14 (5%) 7 (11%)
total
------------------------------------------------------------------------
\1\ See note 1 for table 1 of this document.
Table 4.--Summary of On-Schedule Postmarketing Commitments (Numbers as
of September 30, 2008)
------------------------------------------------------------------------
On-Schedule
Open PMCs NDA/ANDA (% of Total PMC) BLA (% of Total PMC)\1\
------------------------------------------------------------------------
Pending 544 (54%) 112 (31%)
------------------------------------------------------------------------
Ongoing 166 (17%) 93 (26%)
------------------------------------------------------------------------
Submitted 255 (25%) 74 (21%)
------------------------------------------------------------------------
Combined 965 (96%) 279 (78%)
total
------------------------------------------------------------------------
\1\ See note 1 for table 1 of this document.
Table 5.--Summary of Off-Schedule Postmarketing Commitments (Numbers as
of September 30, 2008)
------------------------------------------------------------------------
Off-Schedule
Open PMCs NDA/ANDA (% of Total PMC) BLA (% of Total PMC)\1\
------------------------------------------------------------------------
Delayed 39 (4%) 76 (21%)
------------------------------------------------------------------------
Terminated 4 (0.4%) 2 (1%)
------------------------------------------------------------------------
Combined 43 (4%) 78 (22%)
total
------------------------------------------------------------------------
\1\ See note 1 for table 1 of this document.
Table 6.--Summary of Concluded Postmarketing Requirements and
Commitments (October 1, 2007 to October 1, 2008)
------------------------------------------------------------------------
NDA/ANDA (% of Total) BLA (% of Total)\1\
------------------------------------------------------------------------
Concluded PMRs
------------------------------------------------------------------------
Requiremen 12 (80%) 7 (70%)
t met
(fulfille
d)
------------------------------------------------------------------------
[[Page 45872]]
Requiremen 1 (7%) 0
t not met
(released
and new
revised
requireme
nt
issued)
------------------------------------------------------------------------
Requiremen 2 (13%) 3 (30%)
t no
longer
feasible
or
product
withdrawn
(released
)
------------------------------------------------------------------------
Total 15 10
------------------------------------------------------------------------
Concluded PMCs
------------------------------------------------------------------------
Commitment 94 (86%) 30 (97%)
met
(fulfille
d)
------------------------------------------------------------------------
Commitment 3 (3%) 0
not met
(released
and new
revised
requireme
nt/
commitmen
t issued)
------------------------------------------------------------------------
Commitment 12 (11%) 1 (3%)
no longer
feasible
or
product
withdrawn
(released
)
------------------------------------------------------------------------
Total 109 31
------------------------------------------------------------------------
\1\ See note 1 for table 1 of this document.
Dated: August 31, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-21302 Filed 9-3-09; 8:45 am]
BILLING CODE 4160-01-S